Mylan Chairman Sees Novartis, Pfizer as Better Fit for Co.: FD
2015-05-28 04:53:25.624 GMT
By Celeste Perri
(Bloomberg) -- Mylan isn’t for sale to Israeli company
Teva, Het Financieele Dagblad reports, citing interview with
Mylan Chairman Robert Coury.
* Sees a takeover by Pfizer as a possibility, following a
successful Mylan bid for Perrigo
* Says Novartis is also a “fantastic” company
* Says a cooperation with either company would have real
strategic, industrial logic, with “big advantages.”
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Celeste Perri in Amsterdam at +31-20-589-8505 or
cperri@bloomberg.net
To contact the editors responsible for this story:
Vidya Root at +33-1-5365-5018 or
vroot@bloomberg.net
Jurjen van de Pol
2015-05-28 04:53:25.624 GMT
By Celeste Perri
(Bloomberg) -- Mylan isn’t for sale to Israeli company
Teva, Het Financieele Dagblad reports, citing interview with
Mylan Chairman Robert Coury.
* Sees a takeover by Pfizer as a possibility, following a
successful Mylan bid for Perrigo
* Says Novartis is also a “fantastic” company
* Says a cooperation with either company would have real
strategic, industrial logic, with “big advantages.”
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Celeste Perri in Amsterdam at +31-20-589-8505 or
cperri@bloomberg.net
To contact the editors responsible for this story:
Vidya Root at +33-1-5365-5018 or
vroot@bloomberg.net
Jurjen van de Pol